The stock price of Zimmer Biomet Holdings Inc (NYSE: ZBH) has dropped by -0.16 compared to previous close of 127.72. Despite this, the company has seen a fall of -0.03% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-10 that Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is It Worth Investing in Zimmer Biomet Holdings Inc (NYSE: ZBH) Right Now?
Zimmer Biomet Holdings Inc (NYSE: ZBH) has a price-to-earnings ratio of 26.09x that is above its average ratio. Additionally, the 36-month beta value for ZBH is 1.03. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 9 rating it as “overweight,” 9 rating it as “hold,” and 1 rating it as “sell.”
The public float for ZBH is 204.81M and currently, short sellers hold a 2.31% ratio of that float. The average trading volume of ZBH on April 12, 2024 was 1.46M shares.
ZBH’s Market Performance
ZBH’s stock has seen a -0.03% decrease for the week, with a -0.54% drop in the past month and a 3.48% gain in the past quarter. The volatility ratio for the week is 1.43%, and the volatility levels for the past 30 days are at 1.46% for Zimmer Biomet Holdings Inc. The simple moving average for the past 20 days is -0.31% for ZBH’s stock, with a 4.53% simple moving average for the past 200 days.
Analysts’ Opinion of ZBH
Many brokerage firms have already submitted their reports for ZBH stocks, with Evercore ISI repeating the rating for ZBH by listing it as a “In-line.” The predicted price for ZBH in the upcoming period, according to Evercore ISI is $125 based on the research report published on January 04, 2024 of the current year 2024.
ROTH MKM, on the other hand, stated in their research note that they expect to see ZBH reach a price target of $120. The rating they have provided for ZBH stocks is “Neutral” according to the report published on October 20th, 2023.
BTIG Research gave a rating of “Buy” to ZBH, setting the target price at $139 in the report published on August 28th of the previous year.
ZBH Trading at 0.74% from the 50-Day Moving Average
After a stumble in the market that brought ZBH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.56% of loss for the given period.
Volatility was left at 1.46%, however, over the last 30 days, the volatility rate increased by 1.43%, as shares surge +0.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.21% upper at present.
During the last 5 trading sessions, ZBH fell by -0.03%, which changed the moving average for the period of 200-days by -10.71% in comparison to the 20-day moving average, which settled at $127.96. In addition, Zimmer Biomet Holdings Inc saw 4.78% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZBH starting from Yi Sang, who sale 1,705 shares at the price of $126.86 back on Mar 07 ’24. After this action, Yi Sang now owns 18,179 shares of Zimmer Biomet Holdings Inc, valued at $216,296 using the latest closing price.
Phipps Chad F, the Sr. VP/Gen Counsel/Secretary of Zimmer Biomet Holdings Inc, sale 26,156 shares at $128.62 during a trade that took place back on Feb 22 ’24, which means that Phipps Chad F is holding 44,145 shares at $3,364,126 based on the most recent closing price.
Stock Fundamentals for ZBH
Current profitability levels for the company are sitting at:
- 0.18 for the present operating margin
- 0.72 for the gross margin
The net margin for Zimmer Biomet Holdings Inc stands at 0.14. The total capital return value is set at 0.07. Equity return is now at value 8.36, with 4.81 for asset returns.
Based on Zimmer Biomet Holdings Inc (ZBH), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at 0.27. The debt to equity ratio resting at 0.47. The interest coverage ratio of the stock is 6.75.
Currently, EBITDA for the company is 2.34 billion with net debt to EBITDA at 2.3. When we switch over and look at the enterprise to sales, we see a ratio of 4.36. The receivables turnover for the company is 5.13for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.61.
Conclusion
In conclusion, Zimmer Biomet Holdings Inc (ZBH) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
